Observational Study to Evaluate the Efficacy of Sustained QUTENZA® Use in Painful Diabetic Peripheral Neuropathy

Eligibility Criteria

• 1. IRB approved written Informed Consent and privacy language as per national regulations will be obtained from the patient or legally authorized representative prior to any study-related procedures (including withdrawal of prohibited medication, if applicable)
• 2. Male or female 18 - 80 years of age
• 3. Diagnosis of painful, distal, symmetrical, sensorimotor polyneuropathy due to diabetes confirmed by the Douleur Neuropathique 4 Interview (DN4I) of at least 3 out of 7
• 4. Baseline PROMIS-29 numeric pain intensity score over the last 7 days ≥ 4 during the screening period
• 5. Stable doses of pain medications for PDPN for more than 4 weeks prior to the screening visit
• 6. Patient agreed not to participate in another interventional study while on treatment
• 1. Pain associated with PDPN in the ankles or above
• 2. Pain that could not be clearly differentiated from, or conditions that might have interfered with the assessment of the PDPN, such as plantar fasciitis, heel spurs, tibial neuropathy, Morton's neuroma, bunions, metatarsalgia, arthritis in feet, peripheral vascular disease (ischemic pain), neurological disorders unrelated to diabetic neuropathy (eg, phantom limb pain from amputation), skin condition in the area of the neuropathy that could alter sensation (eg, plantar ulcer)
• 3. Significant pain (moderate or above) of an etiology other than PDPN (eg, compression-related neuropathies \[eg, spinal stenosis\]), fibromyalgia or arthritis, that may interfere with assessment of PDPN-related pain
• 4. Current foot ulcer or not intact skin as determined by medical examination
• 5. Clinically significant foot deformities or foot amputations
• 6. Any active signs of skin inflammation around onychomycosis sites such as pain, redness, swelling or drainage
• 7. Patient is unwilling to implement proper foot care methods
• 8. Diagnosis of any poorly controlled major psychiatric disorder at the Investigator's discretion
• 9. Evidence of cognitive impairment including dementia that may interfere with patient's ability to complete pain assessments requiring patient's recall of average pain level in the past 24 hours
• 10. Active substance abuse or history of chronic substance abuse within 1 year prior to screening visit or any prior chronic substance abuse (including alcoholism) likely to have reoccurred during the study period as judged by the Investigator
• 11. Participation in any other PDPN related clinical study within 30 days prior to the screening visit
• 12. Previous treatment with QUTENZA
• 13. Hypersensitivity to capsaicin (eg, chili peppers or over-the-counter capsaicin products) or any QUTENZA excipients
• 14. Active malignancy or history of malignancy during the past 5 years prior to screening visit (a history of squamous cell carcinoma or a basal cell carcinoma not involving the area to be treated is allowed)
• 15. Use of transcutaneous nerve or spinal cord stimulators to relieve pain
• 16. Patient, who in the opinion of the Investigator, is not likely to complete the study for any reason